{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Welcome to the Arena from ICR – Conversations with Today's Innovators & Business Leaders","title":"Dr. Marc Hedrick, President & CEO, Plus Therapeutics - The Plus Side: Making groundbreaking developments in cancer research","html":"","width":"100%","height":180,"duration":1721,"description":"Millions of Americans with medical conditions spend years waiting for breakthrough treatments. Today's guest is making extraordinary advances in cancer treatment to significantly improve outcomes.\nToday we're sitting down with Dr. Marc Hedrick, President and CEO at Plus Therapeutics whose stock trades under the symbol PSTV. Previously, Dr. Hedrick served in a number of executive leadership roles, including President, CEO and Director of Cytori Therapeutics, and President and CEO of STEM Source. He's a trained general vascular and plastic surgeon, and former Associate Professor of Surgery and Pediatrics at UCLA. He also served as co-Director of the Laboratory of Regenerative Bioengineering and Repair at UCLA. \nDr. Hedrick received his MD from University of Texas Southwestern Medical School Dallas, and an MBA from the Anderson School at UCLA in 2005. We talked about his company's incredible new technology that is revolutionizing how some cancers can be treated. \nHighlights:\nMarc describes his background, and path to the medical field (2:52)\nHow Plus Therapeutics approaches their work to change outcomes for debilitating diseases (3:34)\nHow Plus Therapeutics targeted treatment differs from traditional radiotherapy (5:19)\nMarc breaks down how the company chooses what types of cancer to develop treatments for (6:11)\nHow Plus Therapeutics is driving innovation (7:39)\nWhat treatments their distinctive drugs can be used for and how they work (9:44)\nPlus Therapeutics partnerships, and what the company looks for in a partner (12:16)\nHow the company managed challenges through the COVID-19 pandemic (13:47)\nCompetition in the CNS space, and the challenges Plus Therapeutics faced introducing a new treatment (15:18)\nFunding, and the company's unique capitalization strategy (16:33)\nThe competitive landscape (18:32)\nPlus Therapeutics leadership team, and value of culture (20:16)\nLocational benefits, and the entrepreneurial ecosystem in Texas (21:42)\nMarc's predictions on the...","thumbnail_url":"https://img.transistorcdn.com/VPbFZOgoHk78hrWlplrfMSrQROUNxI8jcZ2Gv-hyKm4/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9mYmFh/NWFlNGJjY2Y0NGFk/YmM2NWJiMTI4NmVh/OWQ4Yi5wbmc.webp","thumbnail_width":300,"thumbnail_height":300}